|
1
|
Bielinska M, Parviainen H, Kiiveri S,
Heikinheimo M and Wilson DB: Review paper: origin and molecular
pathology of adrenocortical neoplasms. Vet Pathol. 46:194–210.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barlaskar FM and Hammer GD: The molecular
genetics of adrenocortical carcinoma. Rev Endocr Metab Disord.
8:343–348. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Assié G, Antoni G, Tissier F, et al:
Prognostic parameters of metastatic adrenocortical carcinoma. J
Clin Endocrinol Metab. 92:148–154. 2007. View Article : Google Scholar
|
|
4
|
Stojadinovic A, Ghossein RA, Hoos A, et
al: Adrenocortical carcinoma: clinical, morphologic and molecular
characterization. J Clin Oncol. 20:941–950. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dang CV: MYC on the path to cancer. Cell.
30:22–35. 2012. View Article : Google Scholar
|
|
6
|
Sheen JH, Woo JK and Dickson RB: c-myc
alters the DNA damage-induced G2/M arrest in human mammary
epithelial cells. Br J Cancer. 89:1479–1485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Giordano TJ, Kuick R, Else T, et al:
Molecular classification and prognostication of adrenocortical
tumors by transcriptome profiling. Clin Cancer Res. 15:668–676.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Reyniès A, Assié G, Rickman DS, et al:
Gene expression profiling reveals a new classification of
adrenocortical tumors and identifies molecular predictors of
malignancy and survival. J Clin Oncol. 27:1108–1115. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tömböl Z, Szabó PM, Molnár V, et al:
Integrative molecular bioinformatics study of human adrenocortical
tumors: microRNA, tissue-specific target prediction, and pathway
analysis. Endocr Relat Cancer. 16:895–906. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Szabó PM, Tamási V, Molnár V, et al:
Meta-analysis of adrenocortical tumor genomics data: novel
pathogenic pathways revealed. Oncogene. 29:3163–3172. 2010.
View Article : Google Scholar
|
|
11
|
Dong J, Naito M and Tsuruo T: C-myc plays
a role in cellular susceptibility to death receptor-mediated and
chemotherapy-induced apoptosis in human monocytic leukemia u937
cells. Oncogene. 15:639–647. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nesbit CE, Grove LE, Yin X and Prochownik
EV: Differential apoptotic behaviors of c-myc, N-myc and L-myc
oncoproteins. Cell Growth Differ. 9:731–741. 1998.PubMed/NCBI
|
|
13
|
Sklar MD and Prochownik EV: Modulation of
cis-platinum resistance in Friend erythroleukemia cells by c-myc.
Cancer Res. 51:2118–2123. 1991.PubMed/NCBI
|
|
14
|
Prendergast GC: Mechanism of apoptosis by
c-myc. Oncogene. 13:2967–2987. 1999. View Article : Google Scholar
|
|
15
|
Chang YF, Li LL, Wu CW, Liu TY, Lui WY,
Peng FK and Chi CW: Paclitaxel-induced apoptosis in human gastric
carcinoma cell lines. Cancer. 77:14–18. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Das GC, Holiday D, Gallardo R and Haas C:
Taxol-induced cell cycle arrest and apoptosis: dose-response
relationship in lung cancer cells of different wild-type p53 status
and under isogenic condition. Cancer Lett. 26:147–153. 2001.
View Article : Google Scholar
|
|
17
|
Speicher LA, Barone L and Tew KD: Combined
antimicrotubule activity of estra mustine and taxol in human
prostatic carcinoma cell lines. Cancer Res. 16:4433–4440. 1992.
|
|
18
|
Gregory RE and De Lisa AF: Paclitaxel: a
new antineoplastic agent for refractory ovarian cancer. Clin Pharm.
12:401–415. 1993.PubMed/NCBI
|
|
19
|
Fallo F, Pilon C, Barzon L, et al:
Paclitaxel is an effective antiproliferative agent on the human
NCI-H295 adrenocortical carcinoma cell line. Chemotherapy.
44:129–134. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shu CH, Yang WK, Shih YL, Kuo ML and Huang
TS: Cell cycle G2/M arrest and activation of cyclin-dependent
kinases associated with low-dose paclitaxel-induced sub-G1
apoptosis. Apoptosis. 2:463–470. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jordan MA and Wilson L: Microtubules and
actin filaments: dynamic targets for cancer chemotherapy. Curr Opin
Cell Biol. 10:123–130. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Donaldson KL, Goolsby GL and Wahl AF:
Cytotoxicity of anticancer agents cisplatin and taxol during cell
proliferation and the cell cycle. Int J Cancer. 15:847–855. 1994.
View Article : Google Scholar
|
|
23
|
Wang T and Rainey WE: Human adrenocortical
carcinoma cell lines. Mol Cell Endocrinol. 351:58–65. 2012.
View Article : Google Scholar :
|
|
24
|
Singh AM and Dalton S: The cell cycle and
Myc intersect with mechanisms that regulate pluripotency and
reprogramming. Cancer Stem Cell. 5:141–149. 2009. View Article : Google Scholar
|
|
25
|
Schiff PB and Horwitz SB: Taxol stabilizes
microtubles in mouse fibroblast cells. Proc Natl Acad Sci USA.
77:1561–1565. 1980. View Article : Google Scholar
|
|
26
|
Dean M, Fojo T and Bates S: Tumour stem
cells and drug resistance. Nat Rev Cancer. 5:275–284. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Crucitti F, Bellantone R, Ferrante A,
Boscherini M and Crucitti P: The Italian Registry for Adrenal
Cortical Carcinoma: analysis of a multiinstitutional series of 129
patients. The ACC Italian Registry Study Group The ACC Italian
Registry Study Group. Surgery. 119:161–170. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dackiw AP, Lee JE, Gagel RF and Evans DB:
Adrenal cortical carcinoma. World J Surg. 25:914–926. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Allolio B, Hahner S, Weismann D and
Fassnacht M: Management of adrenocortical carcinoma. Clin
Endocrinol Oxf. 60:273–287. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Williamson SK, Lew D, Miller GJ, Balcerzak
SP, Baker LH and Crawford ED: Phase II evaluation of cisplatin and
etoposide followed by mitotane at disease progression in patients
with locally advanced or metastatic adrenocortical carcinoma: a
Southwest Oncology Group Study. Cancer. 88:1159–1165. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bukowski RM, Wolfe M, Levine HS, Crawford
DE, Stephens RL, Gaynor E and Harker WG: Phase II trial of mitotane
and cisplatin in patients with adrenal carcinoma: a Southwest
Oncology Group study. J Clin Oncol. 11:161–165. 1993.PubMed/NCBI
|
|
32
|
Bonacci R, Gigliotti A, Baudin E, et al:
Réseau Comète. Cytotoxic therapy with etoposide and cisplatin in
advanced adrenocortical carcinoma. Br J Cancer. 78:546–549. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wooten MD and King DK: Adrenal cortical
carcinoma. Epidemiology and treatment with mitotane and a review of
the literature. Cancer. 72:3145–3155. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fassnacht M, Terzolo M, Allolio B, et al;
FIRM-ACT Study Group. Combination chemotherapy in advanced
adrenocortical carcinoma. N Engl J Med. 23:2189–2197. 2012.
View Article : Google Scholar
|
|
35
|
Alarcon RM, Rupnow BA, Graeber TG, Knox SJ
and Giaccia AJ: Modulation of c-myc activity and apoptosis in vivo.
Cancer Res. 56:4315–4319. 1996.PubMed/NCBI
|
|
36
|
Hermeking H: The MYC oncogene as a cancer
drug target. Curr Cancer Drug Targets. 3:163–175. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Soucek L, Whitfield J, Martins CP, et al:
Modelling Myc inhibition as a cancer therapy. Nature. 455:679–683.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Amendola D, De Salvo M, Marchese R, et al:
Myc down-regulation affects cyclin D1/cdk4 activity and induces
apoptosis via Smac/Diablo pathway in astrocytoma cell lines. Cell
Prolif. 42:94–99. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
De Salvo M, Maresca G, D’Agnano I, et al:
Temozolomide induced c-Myc-mediated apoptosis via Akt signaling in
MGMT expressing glioblastoma cells. Int J Radiat Biol. 87:518–533.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Frenzel A, Zirath H, Vita M, Albihn A and
Henriksson MA: Identification of cytotoxic drugs that selectively
target tumor cells with MYC overexpression. PLoS One. 6:e279882011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Horwitz SB: Mechanism of action of taxol.
Trends Pharm Sci. 13:134–136. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Demeure MJ, Stephan E, Sinari S, et al:
Preclinical investigation of nanoparticle albumin bound paclitaxel
as a potential treatment for adrenocortical cancer. Ann Surg.
255:140–146. 2012. View Article : Google Scholar
|
|
43
|
Szabó PM, Racz K and Igaz P:
Underexpression of C-myc in adrenocortical cancer: a major
pathogenic event? Horm Metab Res. 43:297–299. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu J, Li XD, Ora A, Heikkilä P, Vaheri A
and Voutilainen R: cAMP-dependent protein kinase activation
inhibits proliferation and enhances apoptotic effect of tumor
necrosis factor-alpha in NCI-H295R adrenocortical cells. J Mol
Endocrinol. 33:511–522. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nau MM, Brooks B, Batey J, et al: L-myc, a
new myc-related gene amplified and expressed in human small cell
lung carcinomas. Nature. 318:69–73. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kohl NE, Kanda N, Schreck RR, Bruns G,
Latt SA, Gilbert F and Alt FW: Transposition and amplification of
oncogene-related sequences in human neuroblastomas. Cell.
35:359–367. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Goga A, Yang D, Tward AD, Morgan DO and
Bishop JM: Inhibition of CDK1 as a potential Therapy for tumors
over-expressing MYC. Nat Med. 13:820–827. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Leibovitz A, McCombs WM III, Johnston D,
McCoy CE and Stinson JC: New human cancer cell culture lines. I.
SW13, small-cell carcinoma of the adrenal cortex. J Natl Cancer
Inst. 51:691–697. 1973.PubMed/NCBI
|
